Predictive Value of Early Changes of Chromogranin A Levels in Patients With Neuroendocrine Tumours Treated With PRRT
The results of the study suggest that an early change in CgA levels might serve as a prognostic factor in NET patients treated with PRRT.
Early Release of Chromogranin A (CgA)
DIAGNOSTIC_TEST: early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).
The CgA level change, We aimed to assess the predictive value of early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT)., 2016-2023
The results of the study suggest that an early change in CgA levels might serve as a prognostic factor in NET patients treated with PRRT.